Home The Word Brain My Amedeo FAQ Privacy About Flying Publisher   


OLIENA
Language recovery after stroke
App | Video | PDF (278 pp) | Web

  Ovarian Neoplasms

  Free Subscription


02.07.2018

1 BMC Cancer
1 Br J Cancer
1 Clin Cancer Res
1 Eur J Obstet Gynecol Reprod Biol
8 Gynecol Oncol
1 Oncol Rep


  Retrieve available abstracts of this week’s articles:
HTML format
Text format
 
 
Single Articles


    BMC Cancer

  1. DA SILVA RF, Cardozo DM, Rodrigues GOL, Souza-Araujo CN, et al
    CAISMOV24, a new human low-grade serous ovarian carcinoma cell line.
    BMC Cancer. 2017;17:756.
    PubMed     Text format     Abstract available


    Br J Cancer

  2. RUSCITO I, Cacsire Castillo-Tong D, Vergote I, Ignat I, et al
    Characterisation of tumour microvessel density during progression of high-grade serous ovarian cancer: clinico-pathological impact (an OCTIPS Consortium study).
    Br J Cancer. 2018 Jun 29. pii: 10.1038/s41416-018-0157.
    PubMed     Text format     Abstract available


    Clin Cancer Res

  3. SIMPKINS F, Jang K, Yoon H, Hew K, et al
    Dual Src and MEK inhibition decreases ovarian cancer growth and targets tumor initiating stem-like cells.
    Clin Cancer Res. 2018 Jun 29. pii: 1078-0432.CCR-17-3697.
    PubMed     Text format     Abstract available


    Eur J Obstet Gynecol Reprod Biol

  4. FELSINGER M, Minar L, Weinberger V, Rovny I, et al
    Secondary cytoreductive surgery - viable treatment option in the management of platinum-sensitive recurrent ovarian cancer.
    Eur J Obstet Gynecol Reprod Biol. 2018;228:154-160.
    PubMed     Text format     Abstract available


    Gynecol Oncol

  5. COSGROVE CM, Tritchler DL, Cohn DE, Mutch DG, et al
    An NRG Oncology/GOG study of molecular classification for risk prediction in endometrioid endometrial cancer.
    Gynecol Oncol. 2017 Nov 10. pii: S0090-8258(17)31459.
    PubMed     Text format     Abstract available

  6. HOROWITZ NS, Larry Maxwell G, Miller A, Hamilton CA, et al
    Predictive modeling for determination of microscopic residual disease at primary cytoreduction: An NRG Oncology/Gynecologic Oncology Group 182 Study.
    Gynecol Oncol. 2017 Nov 22. pii: S0090-8258(17)31371.
    PubMed     Text format     Abstract available

  7. GULERIA S, Jensen A, Kjaer SK
    Risk of borderline ovarian tumors among women with benign ovarian tumors: A cohort study.
    Gynecol Oncol. 2017 Nov 23. pii: S0090-8258(17)31534.
    PubMed     Text format     Abstract available

  8. URBAN RR, Pappas TC, Bullock RG, Munroe DG, et al
    Combined symptom index and second-generation multivariate biomarker test for prediction of ovarian cancer in patients with an adnexal mass.
    Gynecol Oncol. 2018 Jun 18. pii: S0090-8258(18)30946.
    PubMed     Text format     Abstract available

  9. ROSS MS, Burriss ME, Winger DG, Edwards RP, et al
    Unplanned postoperative intensive care unit admission for ovarian cancer cytoreduction is associated with significant decrease in overall survival.
    Gynecol Oncol. 2018 Jun 18. pii: S0090-8258(18)30984.
    PubMed     Text format     Abstract available

  10. VERDOODT F, Dehlendorff C, Friis S, Kjaer SK, et al
    Non-aspirin NSAID use and ovarian cancer mortality.
    Gynecol Oncol. 2018 Jun 27. pii: S0090-8258(18)31000.
    PubMed     Text format     Abstract available

  11. ZHANG XS, Zhang YM, Li B, Fan B, et al
    Risk reduction of endometrial and ovarian cancer after bisphosphonates use: A meta-analysis.
    Gynecol Oncol. 2018 Jun 27. pii: S0090-8258(18)30988.
    PubMed     Text format     Abstract available

  12. CLARK RM, Rice LW, Del Carmen MG
    Thirty-day unplanned hospital readmission in ovarian cancer patients undergoing primary or interval cytoreductive surgery: systematic literature review.
    Gynecol Oncol. 2018 Jun 18. pii: S0090-8258(18)30985.
    PubMed     Text format     Abstract available


    Oncol Rep

  13. YANG T, Cheng J, You J, Yan B, et al
    S100B promotes chemoresistance in ovarian cancer stem cells by regulating p53.
    Oncol Rep. 2018 Jun 27. doi: 10.3892/or.2018.6527.
    PubMed     Text format     Abstract available


Thank you for your interest in scientific medicine.


AMEDEO Ovarian Neoplasms is free of charge.
This policy is made possible thanks to a media sponsorship by Boehringer Ingelheim.

Design: